Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Oncopeptides AB ( (SE:ONCO) ) is now available.
Oncopeptides AB has announced a change in the number of shares and votes following a rights issue, which concluded on September 15, 2025. The total number of shares now stands at 272,706,357, with a share capital increase of SEK 5,216,392.878513. This change reflects the company’s ongoing financial adjustments to support its operations and strategic goals in the biotech industry.
The most recent analyst rating on (SE:ONCO) stock is a Hold with a SEK5.00 price target. To see the full list of analyst forecasts on Oncopeptides AB stock, see the SE:ONCO Stock Forecast page.
More about Oncopeptides AB
Oncopeptides AB is a Swedish biotech company specializing in the research, development, and commercialization of targeted therapies for difficult-to-treat cancers. Utilizing its proprietary Peptide Drug Conjugate (PDC) platform, the company develops compounds that deliver cytotoxic agents directly into cancer cells. Oncopeptides’ flagship drug is being commercialized in Europe, with partnerships in South Korea, the Middle East, and Africa. Founded in 2000, the company employs around 80 people and operates in Sweden, Germany, Austria, Spain, and Italy. It is listed on Nasdaq Stockholm under the ticker ONCO.
Average Trading Volume: 6,445,221
Technical Sentiment Signal: Buy
Current Market Cap: SEK1.33B
Find detailed analytics on ONCO stock on TipRanks’ Stock Analysis page.